Richmond Pharmacology is pleased to confirm our attendance at The Liver Meeting 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), taking place in Washington, DC, from 7–11 November.

Representing Richmond at The Liver Meeting:

  • James Rickard, Chief Scientific Officer


James looks forward to engaging with industry and academic partners to discuss Richmond’s expertise in:

  • Early-phase hepatology and metabolic liver disease trials
  • First-in-human and dose-ranging studies
  • Non-invasive biomarkers and digital health integration
  • Regulatory strategy and multi-regional trial delivery
  • Patient-focused approaches in complex liver studies

If you’re attending AASLD 2025 and seeking a clinical development partner in liver disease research, get in touch to arrange a meeting with James: info@richmondpharmacology.com

Learn more: The Liver Meeting | AASLD

Latest news

Regulatory Pathways to Success

January 9, 2026
Structured pathways to accelerate development and approval.
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event